51. Leucovorin ameliorated methotrexate induced intestinal toxicity via modulation of the gut microbiota.
- Author
-
Huang X, Fang Q, Rao T, Zhou L, Zeng X, Tan Z, Chen L, and Ouyang D
- Subjects
- Animals, Bifidobacterium drug effects, Colon pathology, DNA, Bacterial genetics, Intestinal Diseases microbiology, Male, Mice, Mice, Inbred BALB C, RNA, Ribosomal, 16S genetics, Weight Loss drug effects, Gastrointestinal Microbiome drug effects, Intestinal Diseases chemically induced, Intestinal Diseases drug therapy, Leucovorin therapeutic use, Methotrexate toxicity
- Abstract
Methotrexate (MTX) is a widely used therapeutic agent for the treatment of cancer and autoimmune diseases. However, its efficacy is often limited by adverse effects, such as intestinal toxicity. Although treatment with leucovorin (LV) is the most common method to reduce the toxic effects of MTX, it may also compromise the therapeutic effects of MTX. The gut microbiome has been reported to be associated with the intestinal toxicity of MTX. In this study, the intestinal damage of MTX was ameliorated by treatment with LV. Moreover, the population, diversity, and principal components of the gut microbiota in MTX-treated mice were restored by treatment with LV. The only element of the gut microbiota that was significantly changed after treatment with LV was Bifidobacterium, and supplementation with Bifidobacterium longum ameliorated MTX-induced intestinal damage. In conclusion, our results suggest that the balance and the composition of gut microbiota have an important role in the LV-mediated protection against MTX-induced intestinal toxicity. This work provides foundation of data in support of a new potential mechanism for the prevention of MTX-induced intestinal toxicity., Competing Interests: Declaration of Competing Interest The authors declare that there are no conflicts of interest., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF